Ueland T, Åkerblom A, Ghukasyan T, et al. - Researchers investigated whether activated leukocyte cell adhesion molecule (ALCAM) is related to recurrent events in patients with acute coronary syndromes (ACS). They used a subgroup of 5,165 patients admitted with ACS and involved in the PLATO trial to obtain measurements of ALCAM in serum collected on admission, at discharge, 1 month, and 6 months. They evaluated the link between ALCAM and the composite endpoint and its components including cardiovascular (CV) mortality, non-procedural spontaneous myocardial infarction, or stroke during the 1-year follow-up. Findings revealed an independent link between the admission level of ALCAM and adverse outcomes including CV death, even after adjustment for established inflammatory and cardiac biomarkers, in patients with ACS.